« Abbott Granted CLIA Waiver for CHEM8+ Test Cartridge | Main | More Details About Roche's Companion Diagnostics Strategy »


Karl Schwartz

It may be that the NCI biorepository model could also incorporate your idea, if the participating repositories focus on standardized *diagnostic* analysis ... In which case there sharing the analysis would be would be sufficient to determine eligibility in trials (no need to transfer tissue samples). Which speaks to the need to enable relinking of the biospecimen data with the patient in order to propose studies of interest - to serve translational research. As you know, in the hospital setting, it will be important that the storage and analysis be standardized in order to have confidence in the outcomes of subsequent trials. Doing so, I think, would be a way to partner with the National biospecimen network. See NCI Best Practices http://biospecimens.cancer.gov/practices/

The comments to this entry are closed.

Corporate Underwriters



Search Lab Soft News

  • Google


Subscribe to Lab Soft News (Email and RSS Feeds)

Your email address:

Powered by FeedBlitz

May 2020

Sun Mon Tue Wed Thu Fri Sat
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
Blog powered by Typepad
Member since 12/2005